Watts Gwilliam & Co. LLC Buys 50,744 Shares of Pfizer Inc. $PFE

Watts Gwilliam & Co. LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 176.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 79,423 shares of the biopharmaceutical company’s stock after buying an additional 50,744 shares during the period. Watts Gwilliam & Co. LLC’s holdings in Pfizer were worth $1,918,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. NWF Advisory Services Inc. raised its holdings in Pfizer by 3.2% in the 2nd quarter. NWF Advisory Services Inc. now owns 37,656 shares of the biopharmaceutical company’s stock valued at $913,000 after acquiring an additional 1,162 shares in the last quarter. Total Investment Management Inc. acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $179,000. Orion Porfolio Solutions LLC increased its position in shares of Pfizer by 6.1% during the second quarter. Orion Porfolio Solutions LLC now owns 709,250 shares of the biopharmaceutical company’s stock valued at $17,192,000 after purchasing an additional 40,805 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Pfizer by 16.0% in the second quarter. Thrivent Financial for Lutherans now owns 605,236 shares of the biopharmaceutical company’s stock valued at $14,669,000 after purchasing an additional 83,335 shares in the last quarter. Finally, MASTERINVEST Kapitalanlage GmbH acquired a new position in shares of Pfizer in the second quarter valued at $1,163,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Bank of America lowered their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday. UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Scotiabank started coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target for the company. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $28.22.

Pfizer Price Performance

Shares of Pfizer stock opened at $25.86 on Monday. The stock has a market capitalization of $147.04 billion, a price-to-earnings ratio of 15.04 and a beta of 0.46. The firm’s 50-day moving average price is $25.12 and its two-hundred day moving average price is $24.78. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is presently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.